|
|
Post by BD on Oct 18, 2017 9:11:25 GMT -5
|
|
|
|
Post by novafett on Oct 18, 2017 9:21:22 GMT -5
139 pages! Let me know when you've finished reading it all.  |
|
|
|
Post by ashiwi on Oct 18, 2017 9:37:42 GMT -5
MannKind nabs European patent covering Afrezza system; investors unmoved, shares down 7%
Oct. 18, 2017 10:30 AM ET|About: MannKind Corporation (MNKD)|By: Douglas W. House, SA News Editor
The European Patent Office issues a new patent protecting MannKind's (MNKD -7.4%) dry powder inhaler device used to deliver fast-acting insulin Afrezza. The patent covers the drug delivery device, cartridges and dry powder formulations.
|
|
|
|
Post by BD on Oct 18, 2017 9:44:01 GMT -5
LOL, "investors unmoved" because the news hadn't come out yet...
|
|
|
|
Post by kc on Oct 18, 2017 10:21:39 GMT -5
139 pages! Let me know when you've finished reading it all. |
|
|
|
Post by dh4mizzou on Oct 18, 2017 10:56:26 GMT -5
So is this a "prerequisite" for getting regulatory approval in Europe? If so how soon might we expect to see THAT submission? Or do we have to wait for another partner, similar to BioMM before that can happen?
|
|
|
|
Post by mnholdem on Oct 18, 2017 11:53:08 GMT -5
139 pages! Let me know when you've finished reading it all. I consider it more along the lines of delegating.  |
|
|
|
Post by agedhippie on Oct 18, 2017 13:08:34 GMT -5
So is this a "prerequisite" for getting regulatory approval in Europe? If so how soon might we expect to see THAT submission? Or do we have to wait for another partner, similar to BioMM before that can happen? Patents and EMA approvals are not linked. You can get an EMA approval on a generic or biosimilar - the approval of the Lantus biosimilar is an example. Kicking off patent applications in major markets is good asset protection. |
|
|
|
Post by dreamboatcruise on Oct 18, 2017 13:24:11 GMT -5
So is this a "prerequisite" for getting regulatory approval in Europe? If so how soon might we expect to see THAT submission? Or do we have to wait for another partner, similar to BioMM before that can happen? If the slide presented at Cantor on countries being "targeted" by MNKD means anything, then EU is not planned for near term filing. |
|
|
|
Post by mango on Oct 18, 2017 13:55:52 GMT -5
|
|
|
|
Post by ghochr on Oct 18, 2017 13:57:15 GMT -5
Patents are dime a dozen 😜
|
|
|
|
Post by mango on Oct 18, 2017 14:01:04 GMT -5
Patents are dime a dozen 😜 Negative. |
|
|
|
Post by dreamboatcruise on Oct 18, 2017 14:03:04 GMT -5
Patents are dime a dozen 😜 They cost a heck of a lot more than that to obtain. It doesn't appear that MNKD has patents that are allowing them to block other companies from anything other than trying to directly use FDKP for inhalables, so i'd view their patents as a necessary cost of business but not a source of licensing revenue unless further developed for specific APIs. |
|
|
|
Post by mango on Oct 18, 2017 14:06:29 GMT -5
Patents are dime a dozen 😜 They cost a heck of a lot more than that to obtain. It doesn't appear that MNKD has patents that are allowing them to block other companies from anything other than trying to directly use FDKP for inhalables, so i'd view their patents as a necessary cost of business but not a source of licensing revenue unless further developed for specific APIs. The inhalerS and some manufacturing/equipment used by them is patented. |
|
|
|
Post by dreamboatcruise on Oct 18, 2017 14:19:55 GMT -5
They cost a heck of a lot more than that to obtain. It doesn't appear that MNKD has patents that are allowing them to block other companies from anything other than trying to directly use FDKP for inhalables, so i'd view their patents as a necessary cost of business but not a source of licensing revenue unless further developed for specific APIs. The inhalerS and some manufacturing/equipment used by them is patented. Yes, it appears MNKD is very well protected to prevent someone duplicating Afrezza for many years to come. It doesn't appear that their patents are broad enough to garner licensing revenues from other companies that develop different powdered inhalable products... but at least they've got the strong protection for Afrezza. |
|
